Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 9;113(21):E2973–E2982. doi: 10.1073/pnas.1524924113

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

PMC Copyright notice

Fig. 3. — MS-related changes in the peripheral NK cell compartment. PBMCs derived from healthy individuals (blue circles) and therapy-naïve MS patients characterized by clinically stable disease course (red triangles down) were stained with fluorochrome-conjugated lineage-specific antibodies (CD3, CD56, and CD16) (A) and antibodies directed against activating NK-cell receptors [NKG2D (HD, n = 32; MS, n = 25), DNAM-1 (HD, n = 28; MS, n = 13), 2B4 (HD, n = 33; MS, n = 25), and NKp44 (HD, n = 33; MS, n = 25)] (B); IL-2Rα (CD25, clone B1.49.9) and IL-2Rβ (CD122) chain (HD, n = 33; MS, n = 25) (C); and the content of cytolytic granules GrK (HD, n = 19; MS, n = 15) and perforin (HD, n = 20; MS, n = 15) (D) and analyzed by flow cytometry. (A) Proportions of CD3⁻CD56⁺ NK cells and NK-cell subpopulations (CD56^bright and CD56^dim) in the PB of HDs (n = 43) and therapy-naïve MS patients (n = 33). (B–D) Percentages (left side) and MFIs (right side) of cell surface receptor-positive (B and C) and GrK- or perforin-positive (D) CD56^bright and CD56^dim NK cells. Error bars indicate the SD. P values were calculated with Mann–Whitney test. *P < 0.05; **P < 0.01; ****P < 0.0001.